Synthesis and biological activity of novel 1,2-disubstituted benzene derivatives as factor Xa inhibitors.

[1]  Y. Matsumoto,et al.  Synthesis and biological activity of novel 1,4-diazepane derivatives as factor Xa inhibitor with potent anticoagulant and antithrombotic activity. , 2004, Bioorganic & medicinal chemistry.

[2]  H. Kurihara,et al.  The discovery of YM-60828: a potent, selective and orally-bioavailable factor Xa inhibitor. , 2002, Bioorganic & medicinal chemistry.

[3]  Sung-Hou Kim,et al.  Preparation, characterization, and the crystal structure of the inhibitor ZK-807834 (CI-1031) complexed with factor Xa. , 2000, Biochemistry.

[4]  J. T. Metz,et al.  Non-amidine-containing 1,2-dibenzamidobenzene inhibitors of human factor Xa with potent anticoagulant and antithrombotic activity. , 2000, Journal of medicinal chemistry.

[5]  J. A. Kyle,et al.  1,2-Dibenzamidobenzene inhibitors of human factor Xa. , 2000, Journal of medicinal chemistry.

[6]  J. A. Kyle,et al.  Structure-based design of potent, amidine-derived inhibitors of factor Xa: evaluation of selectivity, anticoagulant activity, and antithrombotic activity. , 2000, Journal of Medicinal Chemistry.

[7]  J. A. Kyle,et al.  N(2)-Aroylanthranilamide inhibitors of human factor Xa. , 2000, Journal of medicinal chemistry.

[8]  Y. Matsumoto,et al.  Antithrombotic effect of YM-75466 is separated from its effect on bleeding time and coagulation time. , 1998, European journal of pharmacology.

[9]  Y. Matsumoto,et al.  Antithrombotic effects of YM-60828 in three thrombosis models in guinea pigs. , 1998, European journal of pharmacology.

[10]  Y. Matsumoto,et al.  Relationship between the antithrombotic effect of YM-75466, a novel factor Xa inhibitor, and coagulation parameters in rats. , 1998, European journal of pharmacology.

[11]  Y. Matsumoto,et al.  Effect of a Synthetic Factor Xa Inhibitor, YM-60828, on Blood Vessel Patency in Combination with a Thrombolytic Agent and on Blood Loss from the Operation Site in a Rat Model of Arterial Thrombosis , 1998, Thrombosis and Haemostasis.

[12]  M. Kayama,et al.  Biochemical and Pharmacological Characterization of YM-60828, a Newly Synthesized and Orally Active Inhibitor of Human Factor Xa , 1998, Thrombosis and Haemostasis.

[13]  Y. Matsumoto,et al.  Comparative Studies of an Orally-active Factor Xa Inhibitor, YM-60828, with other Antithrombotic Agents in a Rat Model of Arterial Thrombosis , 1998, Thrombosis and Haemostasis.

[14]  Y. Matsumoto,et al.  Antithrombotic effects of YM‐60828, a newly synthesized factor Xa inhibitor, in rat thrombosis models and its effects on bleeding time , 1998, British journal of pharmacology.

[15]  Y. Matsumoto,et al.  Comparison of the anticoagulant and antithrombotic effects of YM-75466, a novel orally-active factor Xa inhibitor, and warfarin in mice. , 1998, Japanese journal of pharmacology.

[16]  Y. Matsumoto,et al.  YM-60828, a novel factor Xa inhibitor: separation of its antithrombotic effects from its prolongation of bleeding time. , 1997, European journal of pharmacology.

[17]  P Willett,et al.  Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.

[18]  D. Beeler,et al.  Activation of human prothrombin by highly purified human factors V and X-a in presence of human antithrombin. , 1975, The Journal of biological chemistry.